Przejdź do zawartości

Niedokrwistość sierpowatokrwinkowa

Leczenie zatorów naczyniowych i ostrego zespołu piersiowego

Leczenie bólu

What is the best pharmacologic treatment for sickle cell disease pain crises? (opens new window)

Baker M, Hafner JW.

Źródło‎: Ann Emerg Med 2012;59(6):515-6.

Indeks‎: PubMed 22221839

DOI‎: 10.1016/j.annemergmed.2011.11.026

https://www.ncbi.nlm.nih.gov/pubmed/22221839 (opens new window)

Update on pain management in sickle cell disease. (opens new window)

Ballas SK.

Źródło‎: Hemoglobin 2011;35(5-6):520-9.

Indeks‎: PubMed 21910604

DOI‎: 10.3109/03630269.2011.610478

https://www.ncbi.nlm.nih.gov/pubmed/21910604 (opens new window)

Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. (opens new window)

Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, Alsaigh M, Alalfi A, Alamin M, Gadi A, Mousa SA.

Źródło‎: Thromb Haemost 2007;98(2):392-6.

Indeks‎: PubMed 17721622

https://www.ncbi.nlm.nih.gov/pubmed/17721622 (opens new window)

Nawadnianie (zarządzanie płynami)

Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. (opens new window)

Okomo U, Meremikwu MM.

Źródło‎: Cochrane Database Syst Rev 2012;(6):CD005406.

Indeks‎: PubMed 22696351

DOI‎: 10.1002/14651858.CD005406.pub3

https://www.ncbi.nlm.nih.gov/pubmed/22696351 (opens new window)

Tlenoterapia

Guidelines for the management of the acute painful crisis in sickle cell disease. (opens new window)

Rees DC, Olujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J; British Committee for Standards in Haematology General Haematology Task Force by the Sickle Cell Working Party.

Źródło‎: Br J Haematol 2003;120(5):744-52.

Indeks‎: PubMed 12614204

https://www.ncbi.nlm.nih.gov/pubmed/12614204 (opens new window)

Hyperbaric oxygen therapy for vaso-occlusive crises in nine patients with sickle-cell disease. (opens new window)

Stirnemann J, Letellier E, Aras N, Borne M, Brinquin L, Fain O.

Źródło‎: Diving Hyperb Med 2012;42(2):82-4.

Indeks‎: PubMed 22828815

https://www.ncbi.nlm.nih.gov/pubmed/22828815 (opens new window)

Antybiotyki i respiratoroterapia

Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. (opens new window)

Ballas SK, Files B, Luchtman-Jones L, Benjamin L, Swerdlow P, Hilliard L, Coates T, Abboud M, Wojtowicz-Praga S, Grindel JM.

Źródło‎: Hemoglobin 2004;28(2):85-102.

Indeks‎: PubMed 15182051

https://www.ncbi.nlm.nih.gov/pubmed/15182051 (opens new window)

Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. (opens new window)

Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL.

Źródło‎: N Engl J Med 1995;333(11):699-703.

Indeks‎: PubMed 7637747

DOI‎: 10.1056/NEJM199509143331104

https://www.ncbi.nlm.nih.gov/pubmed/7637747 (opens new window)

Continuous inhaled nitric oxide therapy in a case of sickle cell disease with multiorgan involvement. (opens new window)

Chang WL, Corate LM, Sinclair JM, van der Heyde HC.

Źródło‎: J Investig Med 2008;56(8):1023-7.

Indeks‎: PubMed 19050460

DOI‎: 10.2310/JIM.0b013e31818cb612

https://www.ncbi.nlm.nih.gov/pubmed/19050460 (opens new window)

Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. (opens new window)

Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeschner C, Manci EA.

Źródło‎: N Engl J Med 2000;342(25):1855-65.

Indeks‎: PubMed 10861320

DOI‎: 10.1056/NEJM200006223422502

https://www.ncbi.nlm.nih.gov/pubmed/10861320 (opens new window)